Skip Nav Destination
Issues
15 March 2025
-
Cover Image
Cover Image
Localization of MUC16 in the membrane and cytoplasmic compartments of a renal medullary carcinoma cell. DNA is blue, MUC16 is green, and actin is red, with merged MUC16 and actin appearing as yellow. For details, see the article by Grimm and colleagues on page 1057 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Perspectives
Clinical Trials: Targeted Therapy
Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma
Yago Nieto; Jeremy Ramdial; Benigno Valdez; Peter F. Thall; Roland Bassett; Melissa Barnett; Samer Srour; Chitra Hosing; Amin Alousi; Muzaffar Qazilbash; Uday Popat; Alison Gulbis; Terri Lynn Shigle; Sairah Ahmed; Maria Guillermo Pacheco; Richard Champlin; Elizabeth J. Shpall; Borje S. Andersson
Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Eudocia Q. Lee; Brian M. Alexander; Carlos G. Romo; Jeffrey G. Supko; Nathalie Y.R. Agar; Zahra Talebi; Manmeet S. Ahluwalia; Arati S. Desai; Jorg Dietrich; Thomas J. Kaley; David M. Peereboom; Jennifer Gantchev; Gerard Baquer; Sandro Santagata; Naoko Takebe; Serena Desideri; Joy D. Fisher; Megan Sims; Xiaobu Ye; Keith L. Ligon; Louis B. Nabors; Stuart A. Grossman; Patrick Y. Wen
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Husam A. Alqaisi; David E. Cohn; Jing-Yi Chern; Linda R. Duska; Andrea Jewell; Bradley R. Corr; Ira Seth Winer; Eugenia Girda; Marta A. Crispens; Neesha C. Dhani; Ainhoa Madariaga; Robert C. Grant; Matthew Malaguti; Crystal Lee; Valerie Bowering; Horace Wong; Andrew Poothullil; Vanessa Speers; Lisa Wang; Philippe L. Bedard; John C. Brady; Andrew B. Nixon; Li Chen; Claire O’Connor; William Zamboni; Tawyna McKee; Jeffrey A. Moscow; Amit M. Oza; Stephanie Lheureux
Clinical Trials: Immunotherapy
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study
Caiming Xu; Alessandro Mannucci; Francis Esposito; Helena Oliveres; Vicente Alonso-Orduña; Alfonso Yubero; Carlos Fernández-Martos; Antonieta Salud; Javier Gallego; Marta Martín-Richard; Julen Fernández-Plana; Mónica Guillot; Jorge Aparicio; Marwan Fakih; Scott Kopetz; Jaime Feliu; Joan Maurel; Ajay Goel
Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Anneke L. Eerkens; Martha D. Esajas; Koen Brummel; Annegé Vledder; Nienke van Rooij; Annechien Plat; Stefany B. Avalos Haro; Sterre T. Paijens; Lorian Slagter-Menkema; Ed Schuuring; Naomi Werner; Jos G.W. Kosterink; Bart-Jan Kroesen; Jan C. Wilschut; Toos Daemen; Joost Bart; Hans W. Nijman; Marco de Bruyn; Refika Yigit
MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Federico Cappuzzo; Biagio Ricciuti; Angelo Delmonte; Laura Bonanno; Xiaoyue Wang; Weng Kit Lye; Andreas Görtz; Kalliopi Andrikou; Alessandro Dal Maso; Gabriele Minuti; Maximilian Papi; Joao Victor Alessi; Alessandro Di Federico; Scott Rodig; Mark Magdi Awad; Giulio Metro; Ilaria Attili; Fabiana Vitiello; Sara Pilotto; Stefania Gori; Giulio Rossi; Simonetta Buglioni; Diana Giannarelli; Lorenza Landi
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Michiel M. Smeenk; Judi N.A. van Diessen; Thierry N. Boellaard; Koen J. Hartemink; Jeltje F. de Vries; Vincent van der Noort; Sushil K. Badrising; Emilia C. Owers; Kim Monkhorst; Michel M. van den Heuvel; Willemijn S.M.E. Theelen
Precision Medicine and Imaging
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
Sandra L. Grimm; Menuka Karki; Kyle A. Blum; Jean-Philippe Bertocchio; Rong He; Durga N. Tripathi; Niki M. Zacharias; Justin M. Lebenthal; Rahul A. Sheth; Priya Rao; Giannicola Genovese; Zhen Lu; Robert C. Bast; Davis R. Ingram; Rossana Lazcano; Khalida M. Wani; Wei-Lien Wang; Alexander J. Lazar; Nizar M. Tannir; Cheryl L. Walker; Cristian Coarfa; Pavlos Msaouel
Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Marcelo V. Negrao; Alvaro G. Paula; David Molkentine; Laura Hover; Monique Nilsson; Natalie Vokes; Lars Engstrom; Andrew Calinisan; David M. Briere; Laura Waters; Jill Hallin; Lixia Diao; Mehmet Altan; George R. Blumenschein; Ferdinandos Skoulidis; Jing Wang; Scott E. Kopetz; David S. Hong; Don L. Gibbons; Peter Olson; James G. Christensen; John V. Heymach
Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma
Bach Ardalan; Aaron Ciner; Yasmine Baca; Andrew Hinton; Sourat Darabi; Anup Kasi; Emil Lou; Jose Ignacio Azqueta; Joanne Xiu; Jashodeep Datta; Anthony F. Shields; Andrew Aguirre; Harshabad Singh; Rachna T. Shroff; Michael J. Pishvaian; Sanjay Goel
Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials
David E. Gerber; Claire R. Wynters; Tanushree Prasad; Ronny K. Schnel; Song Zhang; Thomas E. Stinchcombe; Liza C. Villaruz; Joshua M. Bauml; Wade T. Iams; Tejas Patil; Stephen V. Liu; Leora Horn; John M. Hudak; D. Ross Camidge
Translational Cancer Mechanisms and Therapy
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Jonathan Welti; Denisa Bogdan; Ines Figueiredo; Ilsa Coleman; Juan Jiménez Vacas; Kate Liodaki; Franziska Weigl; Lorenzo Buroni; Wanting Zeng; Ilona Bernett; Claudia Bertan; Theodoros I. Roumeliotis; Amandeep Bhamra; Jan Rekowski; Bora Gurel; Antje J. Neeb; Jian Ning; Dapei Li; Veronica S. Gil; Ruth Riisnaes; Susana Miranda; Mateus Crespo; Ana Ferreira; Nina Tunariu; Elisa Pasqua; Nicola Chessum; Matthew Cheeseman; Robert te Poele; Marissa Powers; Suzanne Carreira; Jyoti Choudhary; Paul Clarke; Udai Banerji; Amanda Swain; Keith Jones; Wei Yuan; Paul Workman; Peter S. Nelson; Johann S. de Bono; Adam Sharp
YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Yuki Katayama; Tadaaki Yamada; Keiko Tanimura; Hayato Kawachi; Masaki Ishida; Yohei Matsui; Soichi Hirai; Ryota Nakamura; Kenji Morimoto; Naoki Furuya; Sachiko Arai; Yasuhiro Goto; Yoshihiko Sakata; Kazumi Nishino; Michiko Tsuchiya; Akihiro Tamiya; Go Saito; Satoshi Muto; Takayuki Takeda; Koji Date; Yasuhito Fujisaka; Satoshi Watanabe; Daichi Fujimoto; Hisanori Uehara; Mano Horinaka; Toshiyuki Sakai; Seiji Yano; Shinsaku Tokuda; Koichi Takayama
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Jack R. Andrews; Yohan Kim; Edlira Horjeti; Ali Arafa; Heather Gunn; Aurélie De Bruycker; Ryan Phillips; Daniel Song; Daniel S. Childs; Oliver A. Sartor; Jacob J. Orme; Aadel A. Chaudhuri; Phuoc Tran; Ana Kiess; Philip Sutera; Carole Mercier; Piet Ost; Sean S. Park; Fabrice Lucien
In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRASG12C-Mutant Non–Small Cell Lung Cancer
Ryoji Kato; Hitendra S. Solanki; Hilal Ozakinci; Bina Desai; Harika Gundlapalli; Yu Chi Yang; Ida Aronchik; Mallika Singh; Joseph Johnson; Andriy Marusyk; Theresa A. Boyle; Eric B. Haura
Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Hongxiang Hu; Yan Li; Julia Piasecki; Daniela Hosseyni; Zhicheng Yan; Xianghong Liu; Ken Ogasawara; Simon Zhou; Yiming Cheng
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds